{'fraction_non_alphanumeric': 0.01078582434514638, 'fraction_numerical': 0.007704160246533128, 'mean_word_length': 5.914893617021277, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Depot medroxyprogesterone and vaginal bleeding in the puerperium.

A single intramuscular injection of 150 mg MPA (medroxyprogesterone acetate) administered during the early puerperium is an effective contraceptive which does not interfere with lactation or predispose women to thromboembolic complications. MPA does however involve the risk of prolonged vaginal bleeding. Use of this method of contraception until tubal sterilization could be performed during the 1st postpartum menstrual period has proven psychologically unacceptable for many women. Deferring the 1st injection until a postpartum menstrual period has occurred is more acceptable.